| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8739025 | International Journal of Infectious Diseases | 2018 | 7 Pages |
Abstract
VPA and SAHA have adjunctive potential to World Health Organization-recommended TB treatment regimens. Clinical evaluation of the two drugs with regard to reducing the treatment duration and improving treatment outcomes in TB is warranted.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Martin Rao, Davide Valentini, Alimuddin Zumla, Markus Maeurer,